Zoledronic acid: A review of its use in the treatment of Paget's disease of bone

Drugs

Volumn 67, Issue 5, 2007, Pages 793-804

  Keating, Gillian M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMINOGLYCOSIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CLODRONIC ACID; DIURETIC AGENT; ERGOCALCIFEROL; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

AREA UNDER THE CURVE; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE NECROSIS; BONE PAIN; CALCIUM BLOOD LEVEL; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOCALCEMIA; LEG PAIN; MYALGIA; NAUSEA; NONHUMAN; PAGET BONE DISEASE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; OSTEITIS DEFORMANS; TREATMENT OUTCOME;

ANIMALIA;

EID: 34047203242     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767050-00011     Document Type: Review

References (43)

1. Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology (Oxford) 2004; 43 (8): 955-9
2. Whyte MP. Paget's disease of bone. N Engl J Med 2006 Aug 10; 355 (6): 593-600
3. Cooper C, Schafheutle K, Dennison E, et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999; 14 (2): 192-7
4. Barker DJP, Clough PWL, Guyer PB, et al. Paget's diease of bone in 14 British towns. Br Med J 1977 May 7; 1: 1181-3
5. Selby PL, Davie MWJ, Ralston SH, et al. Guidelines on the management of Paget's disease of bone. Bone 2002 Sep; 31 (3): 366-73
6. Deftos LJ. Treatment of Paget's disease: taming the wild osteoclast. N Engl J Med 2005 Sep 1; 353 (9): 872-5
7. Drake WM, Kendler DL, Brown JP. Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Clin Ther 2001 Apr; 23 (4): 620-6
8. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab 1996; 81 (3): 961-7
9. Miller PD, Brown JP, Siris ES, et al. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999 May; 106 (5): 513-20
10. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995 Jun; 38 (6): 851-8
11. Langston AL, Campbell MK, Fraser WD, et al. Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 2007; 80: 1-9
12. Russell RGG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006 Apr; 1068: 367-401
13. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001; 296 (2): 235-42
14. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006 May 16; 103 (20): 7829-34
15. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006 May; 38 (5): 617-27
16. Kellinsalmi M, Mönkkönen H, Mönkkönen J, et al. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 2005 Dec; 97 (6): 382-91
17. Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002; 55: 210-24
18. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9 (5): 745-51
19. Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone 1999 May; 24 (5 Suppl.): 81-5S
20. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002 Nov; 42 (11): 1228-36
21. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003 Feb; 43 (2): 154-62
22. Booth BP, Rahman A, Ibrahim A, et al. A population pharmacokinetic model for zoledronic acid (Zometa) in patients with bone metastases [abstract no. PIII-20]. Clin Pharmacol Ther 2003 Feb; 73 (2): 67
23. European Medicines Agency. Summary of product characteristics: zoledronic acid [online]. Available from URL: http://emea.eu.int [Accessed 2006 Dec 11]
24. Arden-Cordone M, Siris ES, Lyles KW, et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 1997 May; 60 (5): 415-8
25. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005 Sep 1; 353 (9): 898-908
26. Hosking D, Lyles K, Brown JP, et al. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 2007; 22 (1): 142-8
27. Kurth AA, Kotowa W, Fricke FU, et al. Zoledronic acid in the long-term management of Paget's disease of the bone in Germany - a cost-saving approach? [abstract no. PAR2]. Value Health 2006 Nov-Dec; 9 (6): A220. Plus poster presented at the 9th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2006 Oct 29-31; Copenhagen
28. Lecomte P, Devogelaer JP, Kaufman JM, et al. Cost-effectiveness analysis of Aclasta in Paget's disease of bone in Belgium [abstract no. PMD2]. Value Health 2005 Nov-Dec; 8 (6): A73-4. Plus poster presented at the 8th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2005 Nov 6-8; Florence
29. Siris ES, Lyles KW, Singer FR, et al. Medical management of Paget's disease of bone: indications for treatment and review of current therapies. J Bone Miner Res 2006 Dec; 21 Suppl. 2: P94-8
30. Devogelaer J-P. Modern therapy for Paget's disease of bone: focus on bisphosphonates. Treat Endocrinol 2002; 1 (4): 241-57
31. Lyles KW, Siris ES, Singer FR, et al. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 2001; 16 (8): 1379-87
32. Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996 Oct; 101 (4): 341-8
33. Reginster JY, Colson F, Morlock G, et al. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone: a double-blind, multiple-dosage, placebo-controlled study. Arthritis Rheum 1992 Aug; 35 (8): 967-74
34. Fraser WD, Stamp TC, Creek RA, et al. A double-blind, multicentre, placebo-controlled study of tiludronate in Paget's disease of bone. Postgrad Med J 1997 Aug; 73 (862): 496-502
35. Walsh JP, Ward LC, Stewart GO, et al. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 2004 Apr 1; 34: 747-54
36. Reid IR, Miller P, Hosking D. Paget's disease and bisphosphonates [letter]. N Engl J Med 2005 Dec 15; 353 (24): 2617-8
37. Hosking D. Pharmacological therapy of Paget's and other metabolic bone diseases. Bone 2006 Feb; 38 (2 Suppl. 2): S3-7
38. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 2003; 63 (4): 417-37
39. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006 May 16; 144 (10): 753-61
40. Merigo E, Manfredi M, Meleti M, et al. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006 Aug; 77 (2): 109-17
41. Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med 2006 Nov 30; 355 (22): 2278-81
42. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aus 2005 Apr 18; 182 (8): 413-5
43. European Medicines Agency. Scientific discussion: zoledronic acid [online]. Available from URL: http://emea.eu.int [Accessed 2007 Jan 3]